Monza

• Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations Pending
  2025-520676-26-00 4 Non-small cell lung cancer (NSCLC)
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease Pending
  2025-521154-42-00 4 Sickle Cell Disease
• IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY. Pending
  2025-521259-21-00 6 PSORIATIC ARTHRITIS
• Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukem … Pending
  2025-521390-14-00 4 Acute Myeloid Leukemia
• Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study Pending
  2025-521583-35-00 4 non-small cell lung cancer (NSCLC)
• Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o … Pending
  2025-521632-12-00 5 Patients on Factor Xa inhibitor treatment needing an urgent interventi
• A phase 1/2 study of subcutaneous blinatumomab administration in children with R/R and MRD+ B-ALL Pending
  2025-521671-31-00 9 Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+)
• A Study to Determine the Effectiveness of a Test Drug ([68Ga]BED003) for the Detection of Pancreatic, Colorectal, Gastric, Breast and Ovaria … Pending
  2025-521983-36-00 4 Colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenoc
• Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending
  2025-522019-40-00 9 relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+)
• A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 Pending
  2025-522084-15-00 10 metastatic NSCLC patients
• CITADEL: a study to asess the effectiveness of CITicoline (TRAUSAN) in preventing cognitive decline After DELirium in older adults with prox … Pending
  2025-522306-21-00 4 Cognitive profiles
• Proof-of-Concept Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of Intranasal Cenegermin in Adult Participants … Pending
  2025-522692-29-00 4 Subacute Moderate to Severe Traumatic Brain Injury (TBI)
• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 5 Neoplasm Metastasis
• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t … Pending
  2025-523555-66-00 5 Myelofibrosis
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipien … Recruiting
  2025-521074-34-00 4 2026-05-15 Allogeneic peripheral hematopoietic stem cell transplant
• A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos … Recruiting
  2024-511496-14-00 5 2026-05-14 Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
• A clinical study to test how safe and effective a new inhaled treatment (called L606) is for people with high blood pressure in the lungs du … Recruiting
  2024-517943-29-00 5 2026-04-21 Pulmonary Hypertension associated with interstitial lung disease (WHO
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit … Recruiting
  2025-523204-68-00 4 2026-03-25 HER2-positive breast cancer
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting
  2024-519444-33-00 5 2026-03-12 HER2-expressing endometrial cancer (IHC 3+/2+)
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini … Recruiting
  2025-521558-40-00 5 2026-02-12 Pulmonary Hypertension Associated with Interstitial Lung Disease

Showing 25–48 of 361 trials